Allstate Corp Buys Shares of 5,574 Natera, Inc. $NTRA

Key Points

• Allstate Corp has acquired a new stake in Natera, Inc., purchasing 5,574 shares valued at approximately $788,000.
• The stock has received mixed analyst ratings, with an average rating of "Buy" and a price target averaging $193.19.
• Recent insider selling involved CEO Steven Leonard Chapman selling over 6,111 shares, resulting in a 3.30% decrease in his ownership in the company.

Allstate Corp bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,574 shares of the medical research company's stock, valued at approximately $788,000.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after buying an additional 77,357 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after buying an additional 3,795,315 shares during the period. JPMorgan Chase & Co. grew its stake in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after buying an additional 660,538 shares during the period. Invesco Ltd. grew its stake in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock worth $287,908,000 after buying an additional 245,719 shares during the period. Finally, Lord Abbett & CO. LLC grew its stake in Natera by 5.6% during the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock worth $215,127,000 after buying an additional 80,865 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

NASDAQ:NTRA traded up $4.84 during mid-day trading on Thursday, reaching $167.88. The stock had a trading volume of 842,708 shares, compared to its average volume of 1,500,739. The stock's 50 day simple moving average is $154.54 and its two-hundred day simple moving average is $154.08. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00. The company has a market capitalization of $23.04 billion, a price-to-earnings ratio of -87.90 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the sale, the chief financial officer owned 65,430 shares in the company, valued at $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 875 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $136,027.50. Following the sale, the insider owned 123,859 shares of the company's stock, valued at approximately $19,255,120.14. The trade was a 0.70% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,705 shares of company stock worth $8,743,776. Corporate insiders own 5.63% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Stephens reiterated an "overweight" rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $193.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.